Institutional Knowledge Map (KMap)
Map
Services
How To Use
About
Toggle theme
Loading...
Menu
Lora Inclan
Clinical Research Coordinator III
Cancer Center Division
Map Page
Research Area
clinical trial,
cancer treatment,
immunotherapy,
lymphoma,
oncology,
combination therapy,
cancer,
drug development,
molecular biology,
drug combination
Grants
(4)
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Active
·
2022
·
$0 / $277.3K
·
External
cancer,
drug development,
clinical trial,
molecular biology,
oncology
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 in Subjects with Non-Hodgkins Lymphoma
Active
·
2022
·
$0 / $236.5K
·
External
pharmacokinetics,
oncology,
clinical trial,
safety,
dose escalation
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
2023
·
$0 / $188.6K
·
External
lymphoma,
cancer treatment,
immunotherapy,
clinical trial,
drug combination
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreate
2022
·
$0 / $650.5K
·
External
cancer treatment,
clinical trial,
immunotherapy,
combination therapy,
lymphoma
Collaborations
(5)
Michele Chu-Pilli
Mutual work: 3 Proposals﹒2 Grants
Collaboration Details
Brianna Denton
Mutual work: 4 Proposals﹒3 Grants
Collaboration Details
Carolyn Lane
Mutual work: 3 Proposals﹒2 Grants
Collaboration Details
Patricia Robles Quihuis
Mutual work: 3 Proposals﹒2 Grants
Collaboration Details
Sandra Ortega
Mutual work: 1 Proposal﹒1 Grant
Collaboration Details
4+ Collaborators
$0 / $1.4M Funding
